Last reviewed · How we verify
NCT05412641: FELLAS
Evaluation of the FELLAS Responsible Fatherhood Project
NA trial testing Intervention - Responsible Fatherhood Programming in Responsible Fatherhood in 540 participants. Status unknown.
1 May 2025
Quick facts
| Lead sponsor | Partnership for Maternal & Child Health of Northern New Jersey |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 540 |
| Start date | 20 June 2021 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intervention - Responsible Fatherhood Programming
Conditions studied
- Responsible Fatherhood — all drugs for Responsible Fatherhood →
Sponsor
Partnership for Maternal & Child Health of Northern New Jersey
Who can join
18 and older, male only, with Responsible Fatherhood. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Partnership for Maternal and Child Health of Northern New Jersey, Inc. (PMCH) is implementing a fatherhood project with the goal of strengthening father-child engagement, improving economic stability, and improving healthy marriage/relationship skills among participants. FELLAS serves community-based fathers 18 years of age or older who reside in Essex County, New Jersey and have at least one child under the age of 24. The program model has three components: to improve responsible parenting using 24/7 Dad, an evidence based curriculum; to improve healthy marriage/relationship skills using Couple Communication I, an evidence based relationship and marriage strengthening curriculum that includes home visits; and to improve economic stability using a comprehensive array of services designed to provide an employment assessment, strengthen basic technology skills, and strengthen pre-employment soft skills. Evaluation activities include a self-report questionnaire administered (1) immediately prior to beginning the program (pretest), (2) immediately after completion of the program (posttest), and (3) six months after the posttest. Focus groups will also provide qualitative data concerning the effects of the program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05412641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05412641 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Partnership for Maternal & Child Health of Northern New Jersey
- Last refreshed: 9 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05412641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing